Patents by Inventor Richard M. van Rijn

Richard M. van Rijn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11787787
    Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: October 17, 2023
    Assignee: Purdue Research Foundation
    Inventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S. A. Elsayed
  • Publication number: 20230293523
    Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.
    Type: Application
    Filed: May 22, 2023
    Publication date: September 21, 2023
    Applicant: Purdue Research Foundation
    Inventors: Daniel P. Flaherty, Richard M. van Rijn, Val J. Watts, Jason A. Scott
  • Publication number: 20230250098
    Abstract: In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the consumption of alcohol in a patient. These compounds may be used in treat or prevent alcoholism or an alcohol abuse disorder and show an improved pharmaceutical profile relative to other commonly used compounds.
    Type: Application
    Filed: October 4, 2022
    Publication date: August 10, 2023
    Applicants: University of Health Sciences & Pharmacy in St. Louis, Purdue Research Foundation, The Trustees of Columbia University in the City of New York
    Inventors: Susruta MAJUMDAR, Richard M. VAN RIJN, Soumen CHAKRABORTY, Balazs VARGA, Anna M. GUTRIDGE, Dalibor SAMES
  • Patent number: 11690844
    Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: July 4, 2023
    Assignee: Purdue Research Foundation
    Inventors: Daniel P. Flaherty, Richard M. van Rijn, Val J. Watts, Jason A. Scott
  • Patent number: 11667623
    Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: June 6, 2023
    Assignee: Purdue Research Foundation
    Inventors: Val J. Watts, Richard M. van Rijn, Daniel Patrick Flaherty, Jatinder Kaur
  • Publication number: 20220326229
    Abstract: Assay for real-time simultaneous recruitment of arrestin isoforms (e.g., ?-arrestin), to a receptor, such as a G protein-coupled receptor (e.g., DOR); a biosensor; a bioarray; and a kit.
    Type: Application
    Filed: February 2, 2022
    Publication date: October 13, 2022
    Applicant: Purdue Research Foundation
    Inventors: Richard M. van Rijn, Alexander R. French, Yazan Jamal Ibrahim Meqbil
  • Publication number: 20210155614
    Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
    Type: Application
    Filed: February 2, 2021
    Publication date: May 27, 2021
    Applicant: Purdue Research Foundation
    Inventors: Richard M. Van Rijn, Mark S. Cushman, Markus Lill, Robert J. Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S.A. Elsayed
  • Publication number: 20210100797
    Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.
    Type: Application
    Filed: October 6, 2020
    Publication date: April 8, 2021
    Applicant: Purdue Research Foundation
    Inventors: Daniel P. Flaherty, Richard M. van Rijn, Val J. Watts, Jason A. Scott
  • Patent number: 10954224
    Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: March 23, 2021
    Assignee: Purdue Research Foundation
    Inventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S. A. Elsayed
  • Publication number: 20200239447
    Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.
    Type: Application
    Filed: April 3, 2020
    Publication date: July 30, 2020
    Applicant: Purdue Research Foundation
    Inventors: Val J. Watts, Richard M. van Rijn, Daniel Patrick Flaherty, Jatinder Kaur
  • Publication number: 20200199111
    Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
    Type: Application
    Filed: June 8, 2018
    Publication date: June 25, 2020
    Applicant: Purdue Research Foundation
    Inventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S.A. Elsayed
  • Patent number: 10662176
    Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 26, 2020
    Assignee: Purdue Research Foundation
    Inventors: Val J. Watts, Richard M. van Rijn, Daniel P. Flaherty, Jatinder Kaur
  • Publication number: 20200031785
    Abstract: This present application disclosed a method for the treatment of treating pain, opioid dependence, alcohol use disorder or autism comprising the step of administering to a mammal in need thereof a therapeutically effective amount of one or more compounds of formula (I), or a pharmaceutically acceptable salt thereof, and one or more carriers, diluents, or excipients. Those compounds are selective adenylyl cyclase 1 (AC1) inhibitors, which may provide an effective method of treatment for chronic/inflammatory pain, and prevent opioid dependence and/or reduce opioid dependence.
    Type: Application
    Filed: September 9, 2019
    Publication date: January 30, 2020
    Applicant: Purdue Research Foundation
    Inventors: Val J. Watts, Richard M. van Rijn, Daniel Patrick Flaherty, Jatinder Kaur
  • Patent number: 10457653
    Abstract: This present application disclosed a series of selective adenylyl cyclase 1 (AC1) inhibitors, compounds having a formula or a pharmaceutically acceptable salt thereof, as a pain therapeutic. Those compounds may provide an effective method of treatment for chronic/inflammatory pain. Those compounds may also prevent opioid dependence and/or reduce opioid dependence. Both method and composition matters are within the scope of this invention.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: October 29, 2019
    Assignee: Purdue Research Foundation
    Inventors: Val J. Watts, Richard M. van Rijn, Daniel Patrick Flaherty, Jatinder Kaur
  • Publication number: 20190023688
    Abstract: The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.
    Type: Application
    Filed: July 18, 2018
    Publication date: January 24, 2019
    Applicant: Purdue Research Foundation
    Inventors: Val J. Watts, Richard M. van Rijn, Daniel P. Flaherty, Jatinder Kaur
  • Publication number: 20190002418
    Abstract: This present application disclosed a series of selective adenylyl cyclase 1 (AC1) inhibitors as a pain therapeutic. Those compounds may provide an effective method of treatment for chronic/inflammatory pain. Those compounds may also prevent opioid dependence and/or reduce opioid dependence. Both method and composition matters are within the scope of this invention.
    Type: Application
    Filed: June 29, 2018
    Publication date: January 3, 2019
    Applicant: Purdue Research Foundation
    Inventors: Val J. Watts, Richard M. van Rijn, Daniel P. Flaherty, Jatinder Kaur
  • Publication number: 20110046064
    Abstract: The present invention provides methods of treating or preventing a substance-related disorder using selective delta opioid receptor-1 (DOP-R1) agonists, delta opioid receptor-2 (DOP-R2) antagonists, and/or mu opioid receptor (MOP-R) antagonists, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The methods provided herein further comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and a DOP-R2 antagonist. The methods also comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and an MOP-R antagonist. The methods provided herein further comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and a DOP-R2 antagonist and a MOP-R antagonist. The invention also relates to compositions containing the same. The invention also relates to methods of determining delta opioid receptor specificity of candidate agents.
    Type: Application
    Filed: May 1, 2009
    Publication date: February 24, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Howard L. Fields, Jennifer L. Whistler, Jennifer M. Mitchell, Elyssa B. Margolis, Richard M. van Rijn